Theravance Biopharma TBPH Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's pre-tax income?
- Theravance Biopharma (TBPH) reported pre-tax income of -$6.47M in Q1 2026.
- How has Theravance Biopharma's pre-tax income changed year-over-year?
- Theravance Biopharma's pre-tax income increased by 54.2% year-over-year, from -$14.14M to -$6.47M.
- What is the long-term trend for Theravance Biopharma's pre-tax income?
- Over 4 years (2021 to 2025), Theravance Biopharma's pre-tax income has grown at a -14.9% compound annual growth rate (CAGR), from -$245.96M to $129.25M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.